AKBA Jul 2024 2.500 put
| Previous Close | 1.6000 |
| Open | 1.6000 |
| Bid | 1.4500 |
| Ask | 1.8000 |
| Strike | 2.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 1.6000 - 1.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 21 |
PR NewswireAkebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking.
Simply Wall St.Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
